Synapse

← Human Gene Therapy Clinical Development

Papers in Human Gene Therapy Clinical Development

Page 1 · newest first

  1. The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse BrainHuman Gene Therapy Clinical Development · 2019
  2. Inhibition of miR-203 Ameliorates Osteoarthritis Cartilage Degradation in the Postmenopausal Rat Model: Involvement of Estrogen Receptor αHuman Gene Therapy Clinical Development · 2019
  3. MiR-625-5p Inhibits Cardiac Hypertrophy Through Targeting STAT3 and CaMKIIHuman Gene Therapy Clinical Development · 2019
  4. MicroRNA-4513 Promotes Gastric Cancer Cell Proliferation and Epithelial–Mesenchymal Transition Through Targeting KAT6BHuman Gene Therapy Clinical Development · 2019
  5. The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based ProductsHuman Gene Therapy Clinical Development · 2019
  6. miR-632 Functions as Oncogene in Hepatocellular Carcinoma via Targeting MYCT1Human Gene Therapy Clinical Development · 2019
  7. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and CostHuman Gene Therapy Clinical Development · 2019
  8. LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular CarcinomaHuman Gene Therapy Clinical Development · 2019
  9. Safety and Toxicology of Ocular Gene Therapy with Recombinant AAV Vector rAAV.hCNGA3 in Nonhuman PrimatesHuman Gene Therapy Clinical Development · 2019
  10. Hepatotoxicity and Toxicology of In Vivo Lentiviral Vector Administration in Healthy and Liver-Injury Mouse ModelsHuman Gene Therapy Clinical Development · 2019
  11. A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson DiseaseHuman Gene Therapy Clinical Development · 2019
  12. In Vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus- p53 Injection for Malignant MelanomaHuman Gene Therapy Clinical Development · 2019
  13. Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector–Based Ebola Vaccine (Ad5-EBOV) Virus TiterHuman Gene Therapy Clinical Development · 2018
  14. Ultrasound-Targeted Microbubble Destruction Delivery of Insulin-Like Growth Factor 1 cDNA and Transforming Growth Factor Beta Short Hairpin RNA Enhances Tendon Regeneration and Inhibits Scar Formation In VivoHuman Gene Therapy Clinical Development · 2018
  15. Varinostat Alters Gene Expression Profiles in Aortic Tissues from ApoE −/– MiceHuman Gene Therapy Clinical Development · 2018
  16. Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 MiceHuman Gene Therapy Clinical Development · 2018
  17. Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3 -Linked Achromatopsia Investigated in an Exploratory Dose-Escalation TrialHuman Gene Therapy Clinical Development · 2018
  18. MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1α/VEGF Signaling Pathway by Targeting CAB39Human Gene Therapy Clinical Development · 2018
  19. Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's DiseaseHuman Gene Therapy Clinical Development · 2018
  20. Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine ModelJournal of International Crisis and Risk Communication Research · 2018
  21. Self-Complementary Adeno-Associated Virus–Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine ModelHuman Gene Therapy Clinical Development · 2018
  22. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical PerspectiveHuman Gene Therapy Clinical Development · 2018
  23. A Multicenter, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Cell and Gene Therapy in Knee Osteoarthritis PatientsHuman Gene Therapy Clinical Development · 2018
  24. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in HumansHuman Gene Therapy Clinical Development · 2018
  25. AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's DiseaseHuman Gene Therapy Clinical Development · 2018
  26. In Vitro Human Placental Studies to Support Adenovirus-Mediated VEGF-D ΔNΔC Maternal Gene Therapy for the Treatment of Severe Early-Onset Fetal Growth RestrictionHuman Gene Therapy Clinical Development · 2017
  27. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- hGAA ) Gene Therapy in Children Affected by Pompe DiseaseHuman Gene Therapy Clinical Development · 2017
  28. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene TherapyHuman Gene Therapy Clinical Development · 2017
  29. Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3 -Mutant DogsHuman Gene Therapy Clinical Development · 2017
  30. A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter SystemHuman Gene Therapy Clinical Development · 2017
  31. Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart FailureHuman Gene Therapy Clinical Development · 2017
  32. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSVHuman Gene Therapy Clinical Development · 2017
  33. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?Human Gene Therapy Clinical Development · 2017
  34. Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia SheepHuman Gene Therapy Clinical Development · 2017
  35. Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD PatientsHuman Gene Therapy Clinical Development · 2017
  36. Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck CancerHuman Gene Therapy Clinical Development · 2017
  37. Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularisHuman Gene Therapy Clinical Development · 2017
  38. Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's DiseaseHuman Gene Therapy Clinical Development · 2017
  39. Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial HypercholesterolemiaHuman Gene Therapy Clinical Development · 2017
  40. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain TumorsHuman Gene Therapy Clinical Development · 2017
  41. Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR +/− Rhesus MacaquesHuman Gene Therapy Clinical Development · 2017
  42. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG MiceHuman Gene Therapy Clinical Development · 2017
  43. Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral VectorsHuman Gene Therapy Clinical Development · 2016
  44. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko MiceHuman Gene Therapy Clinical Development · 2016
  45. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NISHuman Gene Therapy Clinical Development · 2016
  46. Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's DiseaseHuman Gene Therapy Clinical Development · 2016
  47. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or GliosarcomaHuman Gene Therapy Clinical Development · 2016
  48. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in ChimpanzeesHuman Gene Therapy Clinical Development · 2016
  49. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or GliosarcomaHuman Gene Therapy Clinical Development · 2016
  50. Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An InterviewHuman Gene Therapy Clinical Development · 2016